117 related articles for article (PubMed ID: 12583816)
1. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
Lewis R; Bagnall AM; King S; Woolacott N; Forbes C; Shirran L; Duffy S; Kleijnen J; ter Riet G; Riemsma R
Health Technol Assess; 2002; 6(14):1-269. PubMed ID: 12583816
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine--a clinical review.
Gregory RK; Smith IE
Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
7. Acute lung injury associated with vinorelbine.
Tanvetyanon T; Garrity ER; Albain KS
J Clin Oncol; 2006 Apr; 24(12):1952-3. PubMed ID: 16622272
[No Abstract] [Full Text] [Related]
8. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
9. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness analysis: a reader's guide].
Vergnenègre A
Rev Mal Respir; 2003 Feb; 20(1 Pt 1):116-25. PubMed ID: 12709640
[TBL] [Abstract][Full Text] [Related]
11. Current status of vinorelbine for breast cancer.
Smith GA
Oncology (Williston Park); 1995 Aug; 9(8):767-73; discussion 774, 776, 779. PubMed ID: 7577376
[TBL] [Abstract][Full Text] [Related]
12. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
13. Commentary on "A review of vinorelbine in the treatment of breast cancer".
Ibrahim NK
Clin Breast Cancer; 2001 Oct; 2(3):236. PubMed ID: 11899419
[No Abstract] [Full Text] [Related]
14. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
Coukell AJ; Noble S; Faulds D
Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
[TBL] [Abstract][Full Text] [Related]
15. Vinorelbine-induced chemotherapy port extravasation.
Das CK; Gogia A
Lancet Oncol; 2016 Dec; 17(12):e568. PubMed ID: 27924755
[No Abstract] [Full Text] [Related]
16. UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):50-5. PubMed ID: 11098494
[TBL] [Abstract][Full Text] [Related]
17. A review of vinorelbine in the treatment of breast cancer.
Domenech GH; Vogel CL
Clin Breast Cancer; 2001 Jul; 2(2):113-28. PubMed ID: 11899783
[TBL] [Abstract][Full Text] [Related]
18. MVP and vinorelbine for malignant pleural mesothelioma.
Mordant P; Loriot Y; Soria JC; Deutsch E
Lancet; 2008 Aug; 372(9639):629; author reply 629-30. PubMed ID: 18722865
[No Abstract] [Full Text] [Related]
19. Re: Vinorelbine-induced pancreatitis: a case report.
Raderer M; Kornek G; Scheithauer W
J Natl Cancer Inst; 1998 Feb; 90(4):329. PubMed ID: 9486821
[No Abstract] [Full Text] [Related]
20. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
